<?xml version='1.0' encoding='utf-8'?>
<document id="24162246"><sentence text="Concomitant proton pump inhibitors with mycophenolate mofetil and the risk of rejection in kidney transplant recipients."><entity charOffset="40-61" id="DDI-PubMed.24162246.s1.e0" text="mycophenolate mofetil" /></sentence><sentence text="Recent pharmacokinetic studies have demonstrated that proton pump inhibitors (PPI) reduce exposure of mycophenolic acid"><entity charOffset="102-119" id="DDI-PubMed.24162246.s2.e0" text="mycophenolic acid" /></sentence><sentence text=" However, the clinical significance of this drug-drug interaction on transplantation outcomes has not been determined" /><sentence text="" /><sentence text="This was a retrospective cohort study in kidney transplant recipients who were prescribed rabbit antithymocyte globulin, calcineurin inhibitor, mycophenolate mofetil, and steroids"><entity charOffset="144-165" id="DDI-PubMed.24162246.s5.e0" text="mycophenolate mofetil" /><entity charOffset="171-179" id="DDI-PubMed.24162246.s5.e1" text="steroids" /><pair ddi="false" e1="DDI-PubMed.24162246.s5.e0" e2="DDI-PubMed.24162246.s5.e0" /><pair ddi="false" e1="DDI-PubMed.24162246.s5.e0" e2="DDI-PubMed.24162246.s5.e1" /></sentence><sentence text=" We evaluated the impact of PPI use on the 1-year rates of biopsy-proven acute rejection (BPAR)" /><sentence text="" /><sentence text="Two hundred thirteen patients who were prescribed PPI were compared with 384 patients who were on standard acid-suppressive therapy with ranitidine"><entity charOffset="137-147" id="DDI-PubMed.24162246.s8.e0" text="ranitidine" /></sentence><sentence text=" BPAR occurred in similar rates in both groups (15% vs" /><sentence text=" 12%; P=0" /><sentence text="31)" /><sentence text=" In a multivariable analysis, black race was associated with a higher risk of rejection (risk ratio [RR], 2" /><sentence text="38; 95% confidence interval [CI], 1" /><sentence text="41-4" /><sentence text="03)" /><sentence text=" While controlling for rejection risk factors, PPI exposure was associated with an increased risk of rejection in black patients (RR, 1" /><sentence text="93; 95% CI, 1" /><sentence text="18-3" /><sentence text="16) but not in non-black patients (RR, 0" /><sentence text="54; 95% CI, 0" /><sentence text="19-1" /><sentence text="49)" /><sentence text=" At 1 year, BPAR type, BPAR grade, patient and graft survival, graft function, and time to BPAR were not associated with PPI exposure" /><sentence text="" /><sentence text="In this retrospective study, PPI use in the first transplant year was associated with an increased risk for BPAR in black patients but not in non-black patients" /><sentence text=" It is possible that a reduction in mycophenolic acid exposure contributed to the increased risk"><entity charOffset="36-53" id="DDI-PubMed.24162246.s26.e0" text="mycophenolic acid" /></sentence><sentence text="" /></document>